Shopping Cart 0
Cart Subtotal
USD 0

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Vascular Endothelial Growth Factor B-Pipeline Review, H2 2018'; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 7 molecules.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

The report 'Vascular Endothelial Growth Factor B-Pipeline Review, H2 2018' outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 3 respectively.

Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Diabetic Retinopathy, Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

- The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects

- The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Overview

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Companies Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

CSL Ltd

Formycon AG

Momenta Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Drug Profiles

(aflibercept + nesvacumab)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-346-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziv-aflibercept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Discontinued Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)-Product Development Milestones

Featured News & Press Releases

Sep 13, 2018: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

Aug 17, 2018: FDA approves EYLEA (aflibercept) injection sBLA in wet age-related macular degeneration

Aug 13, 2018: Regeneron Provides Regulatory Update on EYLEA (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Aug 01, 2018: Bayer receives approval of new treatment regimen for Eylea in the EU

May 11, 2018: Bayer receives approval for Eylea in China

Mar 20, 2018: Aflibercept shows promising data for nonproliferative DR

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 28, 2018: Regeneron Letter to Healthcare Professionals Re: EYLEA (aflibercept) Injection

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Jan 03, 2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept)

Dec 21, 2017: Bayer Yakuhin Announces Results on EYLEA at the 11th Asia Pacific Retinal Vitreological Society (APVRS)

Dec 11, 2017: Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD

Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program

Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Alteogen Inc, H2 2018

Pipeline by Benitec Biopharma Ltd, H2 2018

Pipeline by CSL Ltd, H2 2018

Pipeline by Formycon AG, H2 2018

Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Therapeutic Products under Development, Key Players in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Therapeutics, Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Pipeline Overview, Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Pipeline, Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) Pipeline Assessment


Companies

Alteogen Inc

Benitec Biopharma Ltd

CSL Ltd

Formycon AG

Momenta Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc